Now it is poised to release data from a crucial trial of its depression drug, TC-5214, an event that, in the view of Leerink Swann analyst Joshua Schimmer, represents "one of the most important catalysts in biotech through year-end.& [...]
Posted On : Oct, 04 2011 | Comments : 0